The Effects Of PPARγ Agonist Rosiglitazone On Proliferation And Apoptosis In Human Prostate Adenocarcinoma Cell Line LNCAP

Prostatic carcinoma is the common malignant tumor in male reproductive system.As life expectancy increases,the improvement of diagnostic techniques and changes in lifestyle and the incidence of prostate cancer has been rising.In the United States,the incidence of prostate cancer tumors accounted for 10%of men and one-third the time of diagnosis is late,the mortality rate for men accounted for the second tumor mortality.In China is no exception,the incidence rate of Prostate cancer in older men in our country has shown a number of trend of increasing,Prostate cancer is the third place in the urinary system tumors now, it has seriously affected the health of older men.As a result of China's huge population base,Prostate cancer is expected to be an important tumor which impact on China's socio-economic development in the next few years.As a result of the high morbidity and high mortality rates of prostate cancer,it have been a hot and difficult theme to be concerned to researchers.In recent years,at home and abroad,the treatment of prostate cancer,has made substantial progress. Surgical resection,endocrine therapy,radiotherapy,immunotherapy,and many other treatment methods are applied to prostate cancer.Recent studys showed that there were close relationship between peroxisome proliferators-activated receptorsγ(PPARγ)and prostatic carcinoma.PPARγhas anti-prostatic carcinoma effect after being activated which then maybe a new site in curing and preventing prostatic carcinoma.PPARγagonists Thiazolidinediones(Thiazolidinedione, TDZs) is a synthetic anti-diabetic drugs,play an important role in metabolic regulation;rosiglitazone(Rosiglitazone,ROZ) is one of TDZ drugs.In this experiment,we observed the effects of human prostate adenocarcinoma cell line LNCAP treated by ROZ.The effect of PPARy agonists on the role of prostate cancer cells is definituded and the mechanism is Preliminary studied.Objective:To investigate the effects of Rosiglitazone on proliferation and apoptosis of human prostate adenocarcinoma cell line LNCAP in vitro.The effect of PPARy agonists on the role of prostate cancer cells is definituded and the mechanism is Preliminary studied.Methods:After LNCAP cells were treated with ROZ for 24,48,72 hours, MTT assay was used to detect the changes in growth LNCAP.LNCAP cell apoptosis was evaluated by flow cytometry and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling(TUNEL).The expression levels of Caspase-3 were examined in LNCAP cells by Western Blot.Results:ROZ significantly inhibited cell growth of LNCAP cells.At concentration of 100μmol/L,ROZ showed a high inhibitory rate of 78.58%after 72 h treatment.Flow cytomewtry showed a significant increase in the number of apoptosis cells,and it reached 48.11%after ROZ(100μmol/L ) treatment for 72 h.At the same time,TUNEL staining positive cells significantly increased in ROZ treated group compared to the control.Western Blot showed that ROZ enhanced the expression of Caspase-3,a critical protein inducing cell apoptosis.Conclusions:Rosiglitazone inhibits cell growth of human prostateadenocarcinoma cell line LNCAP by inducing cell apoptosis in vitro. ROZ might become a new drug to treat patients with prostate cancer.